Patent ID: 7750021

Claim:
A compound of Formula I: in which: n is 1 or 2; A is chosen from —C(O)OR 9 , —OP(O)(OR 9 ) 2 , —P(O)(OR 9 ) 2 , —S(O) 2 OR 9 , —P(O)(R 9 )OR 9 and 1H-tetrazol-5-yl; and R 9 is chosen from hydrogen and C 1-6 alkyl; X is a bond or is chosen from C 1-4 alkylene, —X 1 OX 2 —, —X 1 NR 10 X 2 —, —X 1 C(O)NR 10 X 2 —, —X 1 NR 10 C(O)X 2 —, —X 1 S(O)X 2 —, —X 1 S(O) 2 X 2 —, —X 1 SX 2 — and C 2-9 heteroarylene; wherein X 1 and X 2 are independently chosen from a bond and C 1-3 alkylene; R 10 is chosen from hydrogen and C 1-6 alkyl; and any heteroarylene of X is optionally substituted by a member of the group chosen from halo and C 1-6 alkyl; Y is selected from: wherein R 11 is hydrogen or C 1-6 alkyl; and the left and right asterisks of Y indicate the point of attachment between either —C(R 2 )(R 3 )— and X of Formula I or between X and —C(R 2 )(R 3 )— of Formula I, respectively; and Y can be optionally substituted with 1 to 3 radicals chosen from chloro, fluoro, methyl, ethyl, cyano and bromo; R 1 is chosen from C 6-10 aryl and C 2-9 heteroaryl; wherein any aryl or heteroaryl of R 1 is optionally substituted by a radical chosen from C 6-10 arylC 0-4 alkyl, C 2-9 heteroarylC 0-4 alkyl, C 3-8 cycloalkylC 0-4 alkyl, C 3-8 heterocycloalkylC 0-4 alkyl or C 1-6 alkyl; wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl group of R 1 can be optionally substituted by 1 to 3 radicals chosen from halo, C 1-6 alkyl, C 1-6 alkoxy, halo-substituted-C 1-6 alkyl and halo-substituted-C 1-6 alkoxy; and any alkyl group of R 1 can optionally have a methylene replaced by an atom or group chosen from —S—, —S(O)—, —S(O) 2 —, —NR 10 — and —O—; wherein R 10 is chosen from hydrogen or C 1-6 alkyl; R 2 , R 3 , R 5 , R 6 , R 7 and R 8 are independently chosen from hydrogen, C 1-6 alkyl, halo, hydroxy, C 1-6 alkoxy, halo-substituted C 1-6 alkyl and halo-substituted C 1-6 alkoxy; R 4 is chosen from hydrogen and C 1-6 alkyl; or R 7 and either R 2 , R 4 or R 5 together with the atoms to which R 2 , R 4 , R 5 and R 7 are attached forms a 4 to 7 member ring; wherein said 4 to 7 member ring is saturated or partially unsaturated; and the pharmaceutically acceptable salts thereof.